IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
85 hedge funds and large institutions have $133M invested in IGM Biosciences in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 5 closing their positions.
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
68% more call options, than puts
Call options by funds: $377K | Put options by funds: $224K
50% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 18
18% more funds holding
Funds holding: 72 → 85 (+13)
0.22% more ownership
Funds ownership: 63.52% → 63.74% (+0.22%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
63% less capital invested
Capital invested by funds: $357M → $133M (-$224M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.83M |
| 2 |
Two Sigma Investments
New York
|
+$848K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$436K |
| 4 |
IFG
Independent Financial Group
San Diego,
California
|
+$410K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$358K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.29M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.11M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.69M |
| 4 |
Goldman Sachs
New York
|
-$3.34M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$1.43M |
IGMS Hedge Fund Activity: Q4 2024 in Review
85 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q4 2024, worth a combined $133M — down 63% from $357M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IGMS positions and 5 closed out — a net gain of 13 holders — while 27 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $1.83M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.29M.
- 85 institutional investors held IGM Biosciences (IGMS) as of Q4 2024, up from 72 in Q3 2024.
- Funds reported $133M of IGM Biosciences stock for Q4 2024, down 63% quarter-over-quarter.
- 18 funds opened new IGM Biosciences positions in Q4 2024 and 5 closed out, a net change of +13 holders.
- The largest IGM Biosciences buyer in Q4 2024 was BlackRock, an estimated $1.83M added.
- The largest IGM Biosciences seller in Q4 2024 was T. Rowe Price Associates, an estimated $5.29M sold.
Based on aggregated 13F filings for Q4 2024.